8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Feb 24, 2026·SEC
Globus Medical, Inc.(GMED)Earnings, Financials & Key Ratios
GMED•NYSE
20.2× P/E·Price updated Jun 19, 2026
AboutGlobus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Show more
- Revenue$2.94B+16.7%
- EBITDA$600M+42.8%
- Net Income$538M+422.3%
- EPS (Diluted)3.92+422.7%
- Gross Margin67.41%+14.4%
- EBITDA Margin20.41%+22.4%
- Operating Margin16.33%+147.8%
- Net Margin18.3%+347.8%
- ROE12.29%+388.0%
GMED Key Insights
Globus Medical, Inc. (GMED) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 39.4%
- ✓Strong Piotroski F-Score: 9/9
- ✓FCF machine: 20.0% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 30.1%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GMED posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GMED Price & Volume
Globus Medical, Inc. (GMED) stock price & volume — 10-year historical chart
Loading chart...
GMED Growth Metrics
Globus Medical, Inc. (GMED) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years18.36%
5 Years30.08%
3 Years42.16%
TTM23.49%
Profit CAGR
10 Years16.91%
5 Years39.37%
3 Years41.42%
TTM216.19%
EPS CAGR
10 Years12.85%
5 Years31.16%
3 Years28.44%
TTM219.4%
Return on Capital
10 Years11.35%
5 Years8.1%
3 Years6.04%
Last Year10.43%
GMED Recent Earnings
Globus Medical, Inc. (GMED) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.12+21.7%
$0.92
Rev
$760M+2.6%
$740M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$1.28+20.8%
$1.06
Rev
$826M+3.1%
$802M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.18+51.1%
$0.78
Rev
$769M+4.7%
$735M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.86+13.2%
$0.76
Rev
$745M+0.4%
$743M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.12vs $0.92+21.7% | $760Mvs $740M+2.6% |
| Q1 2026 | Feb 24, 2026 | $1.28vs $1.06+20.8% | $826Mvs $802M+3.1% |
| Q4 2025 | Nov 6, 2025 | $1.18vs $0.78+51.1% | $769Mvs $735M+4.7% |
| Q3 2025 | Aug 7, 2025 | $0.86vs $0.76+13.2% | $745Mvs $743M+0.4% |
Based on last 12 quarters of dataView full earnings history →
GMED Peer Comparison
Globus Medical, Inc. (GMED) competitors in Orthopedics, spine, and sports medicine — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 ZBH | 17.22B | 87.97 | 24.78 | 7.2% | 9.05% | 5.77% | 0.59 | |
 ATEC | 1.33B | 8.81 | -9.18 | 24.95% | -21.07% | -443.09% | 17.21 | |
 XTNT | 61.8M | 0.44 | 14.69 | 14.21% | 1.5% | 3.68% | 0.56 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 |
Compare GMED vs Peers
Globus Medical, Inc. (GMED) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GMED Income Statement
Globus Medical, Inc. (GMED) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 635.98M | 712.97M | 785.37M | 789.04M | 958.1M | 1.02B | 1.57B | 2.52B | 2.94B | 3.1B |
Revenue Growth % | 12.76% | 12.11% | 10.15% | 0.47% | 21.43% | 6.76% | 53.34% | 60.62% | 16.65% | 23.49% |
Cost of Goods Sold | 150.45M | 159.41M | 179.97M | 217.46M | 239.22M | 263.73M | 548.17M | 1.04B | 957.8M | 996.47M |
COGS % of Revenue | 23.66% | 22.36% | 22.92% | 27.56% | 24.97% | 25.78% | 34.95% | 41.1% | 32.59% | - |
Gross Profit | 485.52M▲ 0% | 553.56M▲ 14.0% | 605.39M▲ 9.4% | 571.58M▼ 5.6% | 718.88M▲ 25.8% | 759.12M▲ 5.6% | 1.02B▲ 34.4% | 1.48B▲ 45.4% | 1.98B▲ 33.5% | 2.1B▲ 0% |
Gross Margin % | 76.34% | 77.64% | 77.08% | 72.44% | 75.03% | 74.22% | 65.05% | 58.9% | 67.41% | 67.86% |
Gross Profit Growth % | 13.1% | 14.01% | 9.36% | -5.59% | 25.77% | 5.6% | 34.41% | 45.43% | 33.51% | - |
Operating Expenses | 323.68M | 384.23M | 433.4M | 460.15M | 546.93M | 531.17M | 887.16M | 1.32B | 1.5B | 1.56B |
OpEx % of Revenue | 50.9% | 53.89% | 55.18% | 58.32% | 57.08% | 51.93% | 56.56% | 52.31% | 51.08% | - |
Selling, General & Admin | 267.82M | 311.59M | 354.76M | 354.76M | 408.15M | 432.12M | 643.41M | 981.05M | 1.32B | 1.37B |
SG&A % of Revenue | 42.11% | 43.7% | 45.17% | 44.96% | 42.6% | 42.25% | 41.02% | 38.94% | 44.79% | - |
Research & Development | 43.68M | 55.5M | 60.07M | 84.52M | 97.35M | 73.02M | 124.01M | 163.75M | 185M | 188.45M |
R&D % of Revenue | 6.87% | 7.78% | 7.65% | 10.71% | 10.16% | 7.14% | 7.91% | 6.5% | 6.29% | - |
Other Operating Expenses | 12.19M | 17.15M | 18.57M | 20.87M | 41.43M | 26.04M | 119.74M | 173.08M | 0 | 1000K |
Operating Income | 161.84M▲ 0% | 169.32M▲ 4.6% | 171.99M▲ 1.6% | 111.43M▼ 35.2% | 171.95M▲ 54.3% | 227.95M▲ 32.6% | 133.14M▼ 41.6% | 165.99M▲ 24.7% | 479.8M▲ 189.1% | 546.37M▲ 0% |
Operating Margin % | 25.45% | 23.75% | 21.9% | 14.12% | 17.95% | 22.29% | 8.49% | 6.59% | 16.33% | 17.62% |
Operating Income Growth % | 4.99% | 4.62% | 1.57% | -35.21% | 54.31% | 32.57% | -41.59% | 24.67% | 189.05% | - |
EBITDA | 203.91M | 210.96M | 224.72M | 174.31M | 241.82M | 296.2M | 277.88M | 420.01M | 599.8M | 828.31M |
EBITDA Margin % | 32.06% | 29.59% | 28.61% | 22.09% | 25.24% | 28.96% | 17.72% | 16.67% | 20.41% | 26.71% |
EBITDA Growth % | 5.7% | 3.46% | 6.53% | -22.43% | 38.73% | 22.49% | -6.19% | 51.15% | 42.8% | 59.34% |
D&A (Non-Cash Add-back) | 42.07M | 41.63M | 52.73M | 62.87M | 69.87M | 68.25M | 144.73M | 254.02M | 120M | 281.94M |
EBIT | 163.32M | 176.88M | 176.75M | 115.47M | 194.86M | 236.25M | 201.85M | 219.7M | 609.9M | 604.44M |
Net Interest Income | 6.61M | 13.28M | 17.41M | 13.95M | 9.3M | 14.23M | 20.13M | -4.19M | 7.14M | 10.89M |
Interest Income | 6.61M | 13.28M | 17.41M | 13.95M | 9.3M | 14.23M | 20.13M | 0 | 7.14M | 10.89M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.19M | 0 | 0 |
Other Income/Expense | 8.09M | 19.28M | 17.96M | 14.47M | 8.45M | 15.07M | 32.25M | -45.27M | 130.1M | 116.94M |
Pretax Income | 169.93M▲ 0% | 188.6M▲ 11.0% | 189.95M▲ 0.7% | 125.9M▼ 33.7% | 180.41M▲ 43.3% | 243.02M▲ 34.7% | 165.39M▼ 31.9% | 120.72M▼ 27.0% | 609.9M▲ 405.2% | 663.31M▲ 0% |
Pretax Margin % | 26.72% | 26.45% | 24.19% | 15.96% | 18.83% | 23.76% | 10.54% | 4.79% | 20.75% | 21.39% |
Income Tax | 62.58M | 32.13M | 34.74M | 23.61M | 31.22M | 52.85M | 42.52M | 17.74M | 72M | 76.57M |
Effective Tax Rate % | 36.83% | 17.04% | 18.29% | 18.76% | 17.3% | 21.75% | 25.71% | 14.69% | 11.81% | 11.54% |
Net Income | 107.35M▲ 0% | 156.47M▲ 45.8% | 155.21M▼ 0.8% | 102.28M▼ 34.1% | 149.19M▲ 45.9% | 190.17M▲ 27.5% | 122.87M▼ 35.4% | 102.98M▼ 16.2% | 537.9M▲ 422.3% | 586.74M▲ 0% |
Net Margin % | 16.88% | 21.95% | 19.76% | 12.96% | 15.57% | 18.59% | 7.83% | 4.09% | 18.3% | 18.92% |
Net Income Growth % | 2.88% | 45.76% | -0.81% | -34.1% | 45.86% | 27.47% | -35.39% | -16.19% | 422.31% | 216.19% |
Net Income (Continuing) | 107.35M | 156.47M | 155.21M | 102.28M | 149.19M | 190.17M | 122.87M | 102.98M | 537.9M | 586.74M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.10▲ 0% | 1.54▲ 40.0% | 1.52▼ 1.3% | 1.01▼ 33.6% | 1.44▲ 42.6% | 1.85▲ 28.5% | 1.07▼ 42.2% | 0.75▼ 29.9% | 3.92▲ 422.7% | 4.25▲ 0% |
EPS Growth % | 1.85% | 40% | -1.3% | -33.55% | 42.57% | 28.47% | -42.16% | -29.91% | 422.67% | 219.4% |
EPS (Basic) | 1.12 | 1.60 | 1.57 | 1.04 | 1.48 | 1.89 | 1.09 | 0.76 | 3.98 | - |
Diluted Shares Outstanding | 97.89M | 101.32M | 102M | 100.97M | 103.62M | 102.64M | 114.63M | 137.86M | 137.22M | 138.19M |
Basic Shares Outstanding | 96.24M | 97.88M | 99.15M | 98.58M | 100.73M | 100.47M | 113.09M | 135.73M | 135.15M | 135.36M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GMED Balance Sheet
Globus Medical, Inc. (GMED) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 620.34M | 630.68M | 687.47M | 821.76M | 864.52M | 983.34M | 1.92B | 2.18B | 2.13B | 2.2B |
Cash & Short-Term Investments | 373.71M | 339.68M | 311.49M | 426.74M | 443.45M | 446.06M | 517.79M | 890.06M | 557.24M | 629.85M |
Cash Only | 118.82M | 139.75M | 195.72M | 239.4M | 193.07M | 150.47M | 467.29M | 784.44M | 526.16M | 560.95M |
Short-Term Investments | 254.89M | 199.94M | 115.76M | 187.34M | 250.38M | 295.59M | 50.5M | 105.62M | 31.09M | 68.9M |
Accounts Receivable | 127.06M | 144.36M | 162.42M | 148.1M | 165.65M | 217.31M | 504.87M | 578.33M | 678.94M | 686.43M |
Days Sales Outstanding | 72.92 | 73.9 | 75.49 | 68.51 | 63.11 | 77.55 | 117.49 | 83.79 | 84.32 | 79.86 |
Inventory | 108.41M | 131.25M | 196.31M | 229.15M | 237M | 298.98M | 848.13M | 659.23M | 759.28M | 772.6M |
Days Inventory Outstanding | 263 | 300.53 | 398.14 | 384.62 | 361.61 | 413.79 | 564.73 | 232.38 | 289.35 | 281.64 |
Other Current Assets | 0 | 100K | 0 | 0 | 0 | 21M | 44.58M | 49.64M | 130.15M | 109.23M |
Total Non-Current Assets | 458.16M | 669.99M | 844.61M | 857.72M | 1.09B | 1.09B | 3.17B | 3.07B | 3.18B | 3.24B |
Property, Plant & Equipment | 143.17M | 171.87M | 199.84M | 216.88M | 221.08M | 243.73M | 646.86M | 611.56M | 628.24M | 618.65M |
Fixed Asset Turnover | 4.44x | 4.15x | 3.93x | 3.64x | 4.33x | 4.20x | 2.42x | 4.12x | 4.68x | 4.90x |
Goodwill | 123.89M | 123.73M | 128.78M | 156.72M | 179.71M | 197.47M | 1.43B | 1.43B | 1.44B | 1.44B |
Intangible Assets | 78.66M | 87.32M | 78.81M | 86.95M | 68.66M | 63.57M | 924.6M | 795.12M | 745.06M | 720.85M |
Long-Term Investments | 56.13M | 263.12M | 409.51M | 358.52M | 562.48M | 495.85M | 75.43M | 66.13M | 0 | 16.68M |
Other Non-Current Assets | 36.28M | 10.36M | 21.74M | 32.04M | 36.33M | 43.31M | 78.59M | 75.1M | 150.6M | 248.4M |
Total Assets | 1.08B▲ 0% | 1.3B▲ 20.6% | 1.53B▲ 17.8% | 1.68B▲ 9.6% | 1.96B▲ 16.5% | 2.08B▲ 6.1% | 5.09B▲ 145.0% | 5.25B▲ 3.3% | 5.3B▲ 1.0% | 5.44B▲ 0% |
Asset Turnover | 0.59x | 0.55x | 0.51x | 0.47x | 0.49x | 0.49x | 0.31x | 0.48x | 0.55x | 0.60x |
Asset Growth % | 16.26% | 20.6% | 17.79% | 9.62% | 16.54% | 6.07% | 144.98% | 3.26% | 0.97% | 15.97% |
Total Current Liabilities | 93.07M | 96.12M | 111.4M | 120.79M | 140.16M | 159.2M | 392.35M | 855.91M | 498.5M | 482.46M |
Accounts Payable | 25.04M | 25.89M | 24.61M | 18.2M | 21.95M | 36.1M | 56.67M | 75.12M | 98.85M | 103.66M |
Days Payables Outstanding | 60.74 | 59.29 | 49.92 | 30.56 | 33.5 | 49.96 | 37.73 | 26.48 | 37.67 | 34.51 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 443.35M | 14.74M | 15.12M |
Deferred Revenue (Current) | 755K | 2.6M | 5.4M | 8.13M | 12.03M | 14.1M | 18.37M | 22.14M | 27.66M | 96.29M |
Other Current Liabilities | 40.42M | 39.3M | 43.91M | 50.73M | 64.18M | 66.66M | 201.85M | 185.56M | 357.25M | 337.34M |
Current Ratio | 6.67x | 6.56x | 6.17x | 6.80x | 6.17x | 6.18x | 4.88x | 2.54x | 4.26x | 4.56x |
Quick Ratio | 5.50x | 5.20x | 4.41x | 4.91x | 4.48x | 4.30x | 2.72x | 1.77x | 2.74x | 2.95x |
Cash Conversion Cycle | 275.18 | 315.14 | 423.7 | 422.57 | 391.22 | 441.38 | 644.48 | 289.68 | 336 | 326.99 |
Total Non-Current Liabilities | 17.65M | 19.04M | 18.22M | 52.4M | 75.71M | 70.55M | 695.78M | 218.5M | 231.01M | 224.78M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 417.4M | 0 | 103.92M | 100.1M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 3.48M | 91.04M | 83.59M | 0 | 212.91M |
Deferred Tax Liabilities | 10.67M | 8.11M | 6.02M | 6.2M | 4.31M | 1.78M | 84.42M | 23.89M | 23.76M | 95.35M |
Other Non-Current Liabilities | 6.98M | 10.92M | 12.2M | 46.19M | 71.4M | 65.3M | 102.92M | 111.03M | 103.34M | 100.02M |
Total Liabilities | 110.72M | 115.15M | 129.63M | 173.19M | 215.88M | 229.75M | 1.09B | 1.07B | 729.51M | 707.24M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 6.01M | 520.4M | 537.19M | 118.66M | 115.22M |
Net Debt | -118.82M | -139.65M | -195.72M | -239.4M | -193.07M | -144.46M | 53.11M | -247.25M | -407.5M | -445.73M |
Debt / Equity | - | - | - | - | - | 0.00x | 0.13x | 0.13x | 0.03x | 0.02x |
Debt / EBITDA | - | - | - | - | - | 0.02x | 1.87x | 1.28x | 0.20x | 0.14x |
Net Debt / EBITDA | -0.58x | -0.66x | -0.87x | -1.37x | -0.80x | -0.49x | 0.19x | -0.59x | -0.68x | -0.54x |
Interest Coverage | - | - | - | - | - | - | - | 52.45x | - | - |
Total Equity | 967.78M▲ 0% | 1.19B▲ 22.5% | 1.4B▲ 18.3% | 1.51B▲ 7.4% | 1.74B▲ 15.6% | 1.85B▲ 6.0% | 4B▲ 116.5% | 4.18B▲ 4.5% | 4.57B▲ 9.5% | 4.73B▲ 0% |
Equity Growth % | 16.31% | 22.5% | 18.3% | 7.4% | 15.61% | 6.03% | 116.53% | 4.49% | 9.48% | 41.36% |
Book Value per Share | 9.89 | 11.70 | 13.75 | 14.92 | 16.81 | 17.99 | 34.88 | 30.30 | 33.33 | 34.24 |
Total Shareholders' Equity | 967.78M | 1.19B | 1.4B | 1.51B | 1.74B | 1.85B | 4B | 4.18B | 4.57B | 4.73B |
Common Stock | 97K | 98K | 99K | 99K | 101K | 100K | 136K | 137K | 135K | 135K |
Retained Earnings | 736.25M | 892.72M | 1.05B | 1.05B | 1.19B | 1.24B | 1.14B | 1.15B | 1.39B | 1.51B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -6.91M | -7.17M | -2.9M | 3.96M | -6.77M | -24.63M | -10.19M | -6.86M | 15.35M | 14.4M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GMED Cash Flow Statement
Globus Medical, Inc. (GMED) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 159.53M | 181.64M | 171.97M | 198.79M | 276.27M | 178.47M | 243.5M | 520.64M | 753.45M | 778.51M |
Operating CF Margin % | 25.09% | 25.48% | 21.9% | 25.19% | 28.84% | 17.45% | 15.52% | 20.67% | 25.64% | - |
Operating CF Growth % | -7.19% | 13.86% | -5.32% | 15.59% | 38.98% | -35.4% | 36.44% | 113.82% | 44.72% | 98.44% |
Net Income | 107.35M | 156.47M | 155.21M | 102.28M | 149.19M | 190.17M | 122.87M | 102.98M | 537.87M | 586.74M |
Depreciation & Amortization | 42.07M | 41.63M | 52.73M | 62.87M | 69.87M | 68.25M | 144.73M | 254.02M | 276.84M | 281.94M |
Stock-Based Compensation | 14.69M | 21.9M | 26.09M | 27.07M | 30.59M | 32.81M | 52.74M | 54.19M | 49.78M | 49.19M |
Deferred Taxes | 8.29M | 971K | 4.3M | -4.34M | -17.61M | -22.22M | -57.79M | -125.9M | 18.63M | 26.08M |
Other Non-Cash Items | 17.66M | 10.54M | 7.09M | 48.49M | 61.5M | 14.72M | 97.54M | 332.89M | -46.95M | -44.97M |
Working Capital Changes | -30.52M | -49.87M | -73.44M | -37.59M | -17.25M | -105.26M | -116.6M | -97.55M | -82.71M | -120.43M |
Change in Receivables | -24.95M | -21.79M | -18.31M | 10.7M | -25.89M | -50.84M | -49.91M | -78.06M | -52.18M | -88.18M |
Change in Inventory | -5.28M | -31.38M | -50.02M | -50.11M | -11.97M | -61.74M | -70.33M | -29.86M | -17.6M | -26.66M |
Change in Payables | 9.84M | -3.01M | 773K | -6.35M | 3.68M | 14.42M | -14.22M | 17.66M | 8.49M | 14.47M |
Cash from Investing | -111.28M | -193.03M | -140.28M | -117.32M | -375.94M | -110.36M | 302.97M | -176.05M | -355.01M | -669.07M |
Capital Expenditures | -51.3M | -59.7M | -70.75M | -63.66M | -56.9M | -74.05M | -78.27M | -115.43M | -164.68M | -168.19M |
CapEx % of Revenue | 8.07% | 8.37% | 9.01% | 8.07% | 5.94% | 7.24% | 4.99% | 4.58% | 5.6% | 5.42% |
Acquisitions | -29.94M | -14.82M | -23.8M | -33.48M | -34.49M | -31.43M | -296.03M | -17.64M | 13.46M | -238.29M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 35M | 0 | 0 | 0 | 0 | 0 | 0 | -275.75M | -23.91M |
Cash from Financing | 1.63M | 32.57M | 24.44M | -38.66M | 54.15M | -109.96M | -231.82M | -27.7M | -679.16M | -25.57M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 11.73M | 39.31M | 31.04M | -104.67M | 0 | -144.49M | -225.56M | -85.79M | -300.45M | -72.96M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -104.67M | 0 | -144.49M | -225.56M | -85.79M | -300.45M | -110M |
Other Financing | -10.11M | -6.74M | -6.6M | 66.01M | 54.15M | 34.53M | -6.26M | 58.09M | -378.71M | 47.39M |
Net Change in Cash | 51.86M▲ 0% | 20.93M▼ 59.6% | 55.98M▲ 167.4% | 43.67M▼ 22.0% | -46.33M▼ 206.1% | -42.6M▲ 8.0% | 316.83M▲ 843.7% | 317.15M▲ 0.1% | -258.28M▼ 181.4% | 99.68M▲ 0% |
Free Cash Flow | 108.23M▲ 0% | 121.95M▲ 12.7% | 101.22M▼ 17.0% | 135.13M▲ 33.5% | 219.38M▲ 62.3% | 104.42M▼ 52.4% | 165.22M▲ 58.2% | 405.21M▲ 145.2% | 588.77M▲ 45.3% | 605.32M▲ 0% |
FCF Margin % | 17.02% | 17.1% | 12.89% | 17.13% | 22.9% | 10.21% | 10.53% | 16.08% | 20.03% | 19.52% |
FCF Growth % | -17.37% | 12.67% | -16.99% | 33.5% | 62.34% | -52.4% | 58.23% | 145.25% | 45.3% | 16.95% |
FCF per Share | 1.11 | 1.20 | 0.99 | 1.34 | 2.12 | 1.02 | 1.44 | 2.94 | 4.29 | 4.38 |
FCF Conversion (FCF/Net Income) | 1.49x | 1.16x | 1.11x | 1.94x | 1.85x | 0.94x | 1.98x | 5.06x | 1.40x | 1.03x |
Interest Paid | 3K | 6K | 79K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 59.11M | 30.55M | 34.14M | 25.44M | 45.03M | 77.82M | 100.59M | 158.51M | 0 | 92.02M |
GMED Key Ratios
Globus Medical, Inc. (GMED) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 11.93% | 14.53% | 11.99% | 7.03% | 9.19% | 10.6% | 4.2% | 2.52% | 12.29% | 13.04% |
Return on Invested Capital (ROIC) | 15.04% | 13.4% | 11.45% | 6.76% | 9.16% | 10.52% | 3.47% | 3.12% | 8.89% | 9.76% |
Gross Margin | 76.34% | 77.64% | 77.08% | 72.44% | 75.03% | 74.22% | 65.05% | 58.9% | 67.41% | 67.86% |
Net Margin | 16.88% | 21.95% | 19.76% | 12.96% | 15.57% | 18.59% | 7.83% | 4.09% | 18.3% | 18.92% |
Debt / Equity | - | - | - | - | - | 0.00x | 0.13x | 0.13x | 0.03x | 0.02x |
Interest Coverage | - | - | - | - | - | - | - | 52.45x | - | - |
FCF Conversion | 1.49x | 1.16x | 1.11x | 1.94x | 1.85x | 0.94x | 1.98x | 5.06x | 1.40x | 1.03x |
Revenue Growth | 12.76% | 12.11% | 10.15% | 0.47% | 21.43% | 6.76% | 53.34% | 60.62% | 16.65% | 23.49% |
Related:GMED Dividend History·GMED Revenue History·GMED Price History·GMED P/E History·GMED Financial Ratios·GMED Institutional Holders
GMED SEC Filings & Documents
Globus Medical, Inc. (GMED) SEC filings — annual & quarterly reports (10-K, 10-Q)
GMED Frequently Asked Questions
Globus Medical, Inc. (GMED) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Globus Medical, Inc. (GMED) reported $3.10B in revenue for fiscal year 2025. This represents a 976% increase from $288.2M in 2010.
Globus Medical, Inc. (GMED) grew revenue by 16.7% over the past year. This is strong growth.
Yes, Globus Medical, Inc. (GMED) is profitable, generating $586.7M in net income for fiscal year 2025 (18.3% net margin).
Dividend & Returns
Globus Medical, Inc. (GMED) has a return on equity (ROE) of 12.3%. This is reasonable for most industries.
Globus Medical, Inc. (GMED) generated $605.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.